Dr. Michael Grossbard MD
Professor of Clinical Medicine, COLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS
Member of the Healthcare Council
Council Member Biography
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's lymphoma, breast, gastrointestinal, and colon cancer. Dr. Grossbard has published extensively on the use of immunotherapy for treatment of cancer, and has consulted for companies such as Genentech, IDEC, Berlex, and Amgen. (This is me - Update Profile)
Employment History
- 2000 - Unspecified
- Professor of Clinical Medicine, COLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS
- 2000 - Unspecified
- Chief of Hematology-Oncology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER
GLG NewsSM Analyses by Michael Grossbard
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Avastin Raises Risk of Clots: New News?
December 1, 2008
Scientists recommend 'black box' for Avastin | www.fiercepharma.com
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
-
Amgen Rewords Label: Less Use of Procrit
August 29, 2008
Amgen Told to Reword Drug Label | www.nytimes.com
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
-
Transparency in Healthcare: How to Assess?
August 29, 2008
Transparency in Healthcare | www.hospitalimpact.org
The author argues that transparency in healthcare will be an important step forward for the consumer.
-
August 29, 2008
Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes. Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
-
NICE States Novel Therapies for Renal Cell Cancer Too Costly
August 28, 2008
UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.
GLG Study Groups with Michael Grossbard(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2218 |
| Oncologists Specializing in Hematologic Malignancies in the U.S. | 413 |
| Breast Oncologists (US) | 300 |
| Council Members who Treat Colon/Colorectal Cancer | 274 |
| Multiple Myeloma Physicians | 263 |
GLG Live Meetings with Michael Grossbard(?)
Michael Grossbard has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.